M.-H. Ryu

741 citations

27 papers · 578 indexed · h-index 13

Impact in

Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
Pulmonary and Respiratory Medicine top 10%
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies

Papers in ⓘ

Gastroenterology 9
- Gastrointestinal Tumor Research and Treatment 9
Oncology 17
- Colorectal Cancer Treatments and Studies 11
- Cancer Treatment and Pharmacology 2

Co-authors: Y-K. Kang (7 shared papers)Jia-Lin Lee (5 shared papers)Heung-Moon Chang (8 shared papers)B-Y. Ryoo (3 shared papers)Dok Hyun Yoon (2 shared papers)Tae‐Won Kim (3 shared papers)H.-M. Chang (5 shared papers)Dae Young Zang (2 shared papers)
Journals: Journal of Clinical Oncology (9 papers)British Journal of Cancer (6 papers)Annals of Oncology (5 papers)Japanese Journal of Clinical Oncology (3 papers)European Journal of Cancer (1 paper)
Partner nations: South Korea Japan Taiwan

In The Last Decade

M.-H. Ryu

26 papers receiving 571 citations

Peers

Countries citing papers authored by M.-H. Ryu

Since Specialization

Citations

This map shows the geographic impact of M.-H. Ryu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.-H. Ryu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.-H. Ryu more than expected).

Fields of papers citing papers by M.-H. Ryu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.-H. Ryu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.-H. Ryu. The network helps show where M.-H. Ryu may publish in the future.

Co-authors

The 25 scholars most cited alongside M.-H. Ryu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M.-H. Ryu Line = papers co-authored together M.-H. Ryu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer British Journal of Cancer ·Jia-Lin Lee, Y-K. Kang, Hye Jin Kang, KH Lee, Dae Young Zang, B-Y. Ryoo, J G Kim, S R Park, Wonseok Kang, D.B. Shin, M.-H. Ryu, Heung-Moon Chang, Tae‐Won Kim, Jin Ho Baek, Young Joo Min	2008	116
2	LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study Annals of Oncology ·Narikazu Boku, M.-H. Ryu, D-Y. Oh, Sang Cheul Oh, Hyun Cheol Chung, Kyung-Woo Lee, Takeshi Omori, Kohei Shitara, S. Sakuramoto, Ick‐Joong Chung, Kensei Yamaguchi, Katsuhiko Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jin‐Shing Chen, L-Y. Bai, L-T. Chen, Y-K. Kang	2020	80
3	Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum British Journal of Cancer ·Dok Hyun Yoon, M.-H. Ryu, Y S Park, Heon‐Jin Lee, C Lee, B-Y. Ryoo, Jia-Lin Lee, H.-M. Chang, T W Kim, Y-K. Kang	2012	70
4	Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation Japanese Journal of Clinical Oncology ·Dok Hyun Yoon, Baek‐Yeol Ryoo, M.-H. Ryu, S.-G. Lee, Sun Moon Hwang, Dong Jin Suh, H.-C. Lee, Tae Won Kim, Cheol Soo Ahn, K.-H. Kim, Deok‐Bog Moon, Y.-K. Kang	2010	66
5	A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer British Journal of Cancer ·H. Kang, Heung-Moon Chang, T W Kim, M.-H. Ryu, H-J Sohn, Jeong Hwan Yook, S. T. Oh, Byung Sup Kim, J S Lee, Y-K. Kang	2008	33
6	Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis Japanese Journal of Clinical Oncology ·Jae‐Cheol Jo, J.-L. Lee, M.-H. Ryu, S. Sym, S. S. Lee, H.-M. Chang, T. W. Kim, J. S. Lee, Y.-K. Kang	2007	32
7	Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy British Journal of Cancer ·H. Kang, Heung-Moon Chang, Tae‐Won Kim, M.-H. Ryu, Hee-Jung Sohn, Jeong Hwan Yook, S. T. Oh, B. S. Kim, J S Lee, Y-K. Kang	2005	31
8	Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity British Journal of Cancer ·K-p Kim, Geundoo Jang, Yuancheng Hong, H-S Lim, Kyun‐Seop Bae, Hei Sung Kim, Sang Soo Lee, J-G Shin, Jia-Lin Lee, M.-H. Ryu, H-M. Chang, Y-K. Kang, T. W. Kim	2011	25
9	Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY) Annals of Oncology ·Yoon‐Koo Kang, Jeong Hwan Yook, Y.-K. Park, Young‐Woo Kim, J. Kim, M.-H. Ryu, Sun Young Rha, Ik‐Joo Chung, I.-H. Kim, Sang Cheul Oh, Chung-Sik Yoo, Jin‐Hyuk Choi, Dae Young Zang, Gil-joong Kim, Y. Lee, Sung Hoon Noh	2019	23
10	Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor Japanese Journal of Clinical Oncology ·Inkeun Park, M.-H. Ryu, S. Sym, S. S. Lee, Gi Young Jang, Tae‐Woo Kim, Heung Moon Chang, J.-L. Lee, H. Lee, Y.-K. Kang	2008	21
11	Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines British Journal of Dermatology ·Sungpil Han, M. Lee, G.H. Park, Seunghyun Bang, Yena Kang, T.W. Kim, J.L. Lee, Heung-Moon Chang, M.-H. Ryu	2009	19
12	Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer Annals of Oncology ·Suk-Won Seo, M.-H. Ryu, Yubin Kang, Kwang Pyo Kim, H.-M. Chang, B-Y. Ryoo, S.B. Kim, Jia-Lin Lee, S.R. Park	2016	14
13	Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer British Journal of Cancer ·J-C. Jo, Jia-Lin Lee, M.-H. Ryu, Heung Moon Chang, Myong Kim, HJ Lee, Hei Sung Kim, J-G Shin, Tae‐Won Kim, Y-K. Kang	2012	13
14	Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study Journal of Clinical Oncology ·S. Lee, S. Lee, Young Il Chun, Minjae Kim, Heung Moon Chang, T. Kim, M.-H. Ryu, Ji-min Lee, J. Lee, Youngho Kang	2007	9
15	Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy Journal of Clinical Oncology ·J.-L. Lee, M.-H. Ryu, H. Kang, Heung-Moon Chang, T.-W. Kim, J. S. Lee, Yoon‐Koo Kang	2005	5
16	A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study. Journal of Clinical Oncology ·M.-H. Ryu, S. H. Park, Baek‐Yeol Ryoo, Seock‐Ah Im, Heejin Kwon, S. S. Lee, S. R. Park, Bongsu Kang, Yoon‐Koo Kang	2011	4
17	A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy Journal of Clinical Oncology ·H. Kang, T. W. Kim, Heung-Moon Chang, M.-H. Ryu, J.H. Yook, S. T. Oh, B. S. Kim, J. S. Lee, W. K. Kim, Y.-K. Kang	2004	4
18	A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study) Annals of Oncology ·Yoon‐Koo Kang, Keisho Chìn, Hyun Cheol Chung, Shigenori Kadowaki, Seung-Taek Oh, Norisuke Nakayama, Kyoung Bun Lee, Hiroki Hara, Ick‐Joong Chung, Masahiro Tsuda, S. Park, Hisashi Hosaka, Shuichi Hironaka, Yoshinori Miyata, M.-H. Ryu, M. Takeuchi, Hideo Baba, Ichinosuke Hyodo, Yung‐Jue Bang, Narikazu Boku	2019	3
19	Effects of Chemotherapy (Anthracyclin, Cyclophosphamide following Docetaxel Regimen) on Sleep, Anxiety, Depression, and Quality of Life in Patients with Breast Cancer Oncology ·Sang-Yhun Ju, Youn Joo Jung, Seungju Lee, Seok Kyeong Kang, M.-H. Ryu, Jee Yeon Kim, Kyung Jin Nam, K. Lee, Ji Hyeon Joo, Youngkyung Jeon, Jae Joon Kim, Ji Hoon Kim, Su Bong Nam, Mi Sook Yun, Hyun Yul Kim	2025	2
20	Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer Journal of Clinical Oncology ·Heung-Moon Chang, Tae‐Woo Kim, J.-H. Ahn, M.-H. Ryu, J. S. Lee, W. K. Kim, Yoon‐Koo Kang	2004	2

About M.-H. Ryu

M.-H. Ryu is a scholar working on Gastroenterology, Oncology, Pulmonary and Respiratory Medicine, Internal Medicine and Dermatology, having authored 27 papers that have together received 578 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (11 papers), Gastrointestinal Tumor Research and Treatment (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Lung Cancer Treatments and Mutations (3 papers), Metastasis and carcinoma case studies (3 papers), Cancer Treatment and Pharmacology (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Gastroenterology (140 citations), Pulmonary and Respiratory Medicine (364 citations), Oncology (295 citations), Hepatology (67 citations) and Surgery (196 citations). M.-H. Ryu has collaborated with scholars based in South Korea, Japan and Taiwan. Frequent co-authors include Y-K. Kang, Jia-Lin Lee, Heung-Moon Chang, B-Y. Ryoo, Dok Hyun Yoon, Tae‐Won Kim, H.-M. Chang, Dae Young Zang, Jeong Hwan Yook and Wonseok Kang. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology, Japanese Journal of Clinical Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact